STOCK TITAN

Crispr Therapeut - CRSP STOCK NEWS

Welcome to our dedicated page for Crispr Therapeut news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on Crispr Therapeut stock.

CRISPR Therapeutics (CRSP) is a clinical-stage biopharmaceutical leader pioneering CRISPR/Cas9 gene editing therapies for serious diseases. This page aggregates official announcements, clinical trial updates, and strategic developments directly from the company and verified sources.

Investors and researchers will find timely updates on therapeutic programs targeting hemoglobinopathies, oncology, and autoimmune disorders. Track regulatory milestones, partnership announcements with industry leaders, and financial performance reports. All content is curated to meet investor needs for decision-making clarity.

Key updates include progress in allogeneic CAR-T cell therapies, hemoglobinopathy treatment approvals, and manufacturing scale-up initiatives. Bookmark this page for structured access to CRISPR Therapeutics' latest scientific advancements and business developments.

Rhea-AI Summary

CRISPR Therapeutics (CRSP) announced promising results from its Phase 1 CARBON trial, evaluating CTX110 for treating large B-cell lymphoma (LBCL). The trial reported a 58% overall response rate (ORR) and a 38% complete response (CR) rate in patients treated at Dose Level 2 and above, with durable responses noted over 18 months. The safety profile was favorable, showing no Grade 3 or higher cytokine release syndrome. CRISPR plans to expand the CARBON trial into a potentially registrational study in Q1 2022, supporting the development of CTX110 as an effective 'off-the-shelf' therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Summary

CRISPR Therapeutics announced a virtual event scheduled for October 12, 2021, at 4:30 p.m. ET to discuss clinical data from its ongoing Phase 1 CARBON trial. This trial evaluates the safety and efficacy of CTX110, an investigational CAR-T therapy targeting CD19 for treating relapsed or refractory B-cell malignancies. Investors and stakeholders can join via a conference call or through a live webcast. CTX110 is a gene-edited allogeneic CAR-T therapy developed by CRISPR Therapeutics, focusing on significant diseases using their proprietary CRISPR/Cas9 technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
conferences clinical trial
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced two poster presentations and an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, scheduled for November 10-14, 2021, in Washington, D.C. The first poster focuses on CRISPR/Cas9 gene-edited CAR-T cells targeting CD33 in acute myeloid leukemia (AML), demonstrating promising preclinical efficacy without long-term toxicity. The joint oral presentation with Nkarta will cover strategies to enhance NK cell efficacy against solid tumors. These presentations highlight CRISPR's commitment to advancing gene-based therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences clinical trial
Rhea-AI Summary

CRISPR Therapeutics announced participation in Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 2:00 p.m. ET. Senior management will present insights on their innovative gene-based medicines targeting serious diseases. A live webcast will be accessible via the Company's website, with a replay available for 14 days post-event. The company is noted for its leading gene editing technology, CRISPR/Cas9, and has collaborations with Bayer and Vertex Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
conferences
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) will participate in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 2:30 p.m. ET. The event aims to showcase the company's advancements in gene-based medicines for serious diseases using its CRISPR/Cas9 platform. A live webcast will be available on the company's website, with a replay accessible for 14 days post-event. CRISPR Therapeutics specializes in various therapeutic areas, including oncology and rare diseases, and collaborates with leading firms like Bayer and Vertex Pharmaceuticals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.13%
Tags
conferences
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) reported strong financial results for Q2 2021, highlighting a net income of $759.2 million, a significant increase from a $79.7 million loss in Q2 2020. The revenue surge to $900.2 million was primarily due to a $900 million upfront payment from Vertex following their collaboration amendment. The company has dosed over 45 patients with CTX001 in ongoing trials for sickle cell disease and beta thalassemia, with enrollment completion expected in Q3 2021. Additionally, CTX130 received Orphan Drug Designation for T-cell lymphoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
Rhea-AI Summary

CRISPR Therapeutics (CRSP) has announced a strategic partnership with Capsida Biotherapeutics to develop gene editing therapies targeting familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. CRISPR will lead the Friedreich’s ataxia program, while Capsida will focus on ALS. The collaboration combines CRISPR's gene-editing technology with Capsida's advanced AAV engineering capabilities, potentially enhancing therapeutic efficacy. Both companies can co-develop and share commercialization costs and profits from their respective programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.99%
Tags
none
-
Rhea-AI Summary

Vertex Pharmaceuticals and CRISPR Therapeutics announced positive results from their investigational CRISPR/Cas9 gene-editing therapy, CTX001, in treating transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD). Data from 22 patients indicated sustained treatment responses, with all TDT patients transfusion-free and SCD patients free from vaso-occlusive crises. The therapy aims to provide a one-time functional cure for these conditions. Ongoing trials are expected to finalize regulatory discussions soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) has announced participation in three virtual investor conferences in June 2021. The events include the Jefferies Virtual Healthcare Conference on June 1 at 1:00 p.m. ET, the William Blair 41st Annual Growth Stock Conference on June 3 at 12:20 p.m. ET, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 3:00 p.m. ET. Live webcasts of these presentations will be accessible on the company's website, and recordings will be available for 14 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
conferences
Rhea-AI Summary

Vertex Pharmaceuticals and CRISPR Therapeutics announced the acceptance of two abstracts for presentation at the EHA 2021 Virtual Congress. The studies focus on CTX001, a gene-editing therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT). Both abstracts detail safety and efficacy results from ongoing clinical trials, with data on patients showing promising follow-up outcomes. CTX001 aims to alleviate severe symptoms by increasing fetal hemoglobin levels, potentially reducing transfusion needs and sickle crises.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences clinical trial
Crispr Therapeut

Nasdaq:CRSP

CRSP Rankings

CRSP Stock Data

3.26B
84.87M
1.67%
77.72%
24.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
Switzerland
ZUG